1
|
Li X, Eastham J, Giltnane JM, Zou W, Zijlstra A, Tabatsky E, Banchereau R, Chang CW, Nabet BY, Patil NS, Molinero L, Chui S, Harryman M, Lau S, Rangell L, Waumans Y, Kockx M, Orlova D, Koeppen H. Automated tumor immunophenotyping predicts clinical benefit from anti-PD-L1 immunotherapy. J Pathol 2024; 263:190-202. [PMID: 38525811 DOI: 10.1002/path.6274] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2023] [Revised: 12/22/2023] [Accepted: 02/14/2024] [Indexed: 03/26/2024]
Abstract
Cancer immunotherapy has transformed the clinical approach to patients with malignancies, as profound benefits can be seen in a subset of patients. To identify this subset, biomarker analyses increasingly focus on phenotypic and functional evaluation of the tumor microenvironment to determine if density, spatial distribution, and cellular composition of immune cell infiltrates can provide prognostic and/or predictive information. Attempts have been made to develop standardized methods to evaluate immune infiltrates in the routine assessment of certain tumor types; however, broad adoption of this approach in clinical decision-making is still missing. We developed approaches to categorize solid tumors into 'desert', 'excluded', and 'inflamed' types according to the spatial distribution of CD8+ immune effector cells to determine the prognostic and/or predictive implications of such labels. To overcome the limitations of this subjective approach, we incrementally developed four automated analysis pipelines of increasing granularity and complexity for density and pattern assessment of immune effector cells. We show that categorization based on 'manual' observation is predictive for clinical benefit from anti-programmed death ligand 1 therapy in two large cohorts of patients with non-small cell lung cancer or triple-negative breast cancer. For the automated analysis we demonstrate that a combined approach outperforms individual pipelines and successfully relates spatial features to pathologist-based readouts and the patient's response to therapy. Our findings suggest that tumor immunophenotype generated by automated analysis pipelines should be evaluated further as potential predictive biomarkers for cancer immunotherapy. © 2024 The Pathological Society of Great Britain and Ireland.
Collapse
Affiliation(s)
- Xiao Li
- Genentech, South San Francisco, CA, USA
| | | | | | - Wei Zou
- Genentech, South San Francisco, CA, USA
| | | | | | | | | | | | | | | | | | | | - Shari Lau
- Genentech, South San Francisco, CA, USA
| | | | | | | | | | | |
Collapse
|
2
|
Baca M, Chalouni C, Koeppen H, Rangell L, Sagolla M, Reichelt M. Development of a Cryo-Pre-Embedding Immunogold Labeling Protocol for the Ultrastructural Localization of PDL1 in Human Tonsils. Microsc Microanal 2023; 29:1123-1124. [PMID: 37613252 DOI: 10.1093/micmic/ozad067.575] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 08/25/2023]
Affiliation(s)
- Miriam Baca
- Genentech, Research Pathology, Center for Advanced Light and Electron Microscopy, South San Francisco, CA, USA
| | - Cecile Chalouni
- Genentech, Research Pathology, Center for Advanced Light and Electron Microscopy, South San Francisco, CA, USA
| | - Hartmut Koeppen
- Genentech, Research Pathology, Center for Advanced Light and Electron Microscopy, South San Francisco, CA, USA
| | - Linda Rangell
- Genentech, Research Pathology, Center for Advanced Light and Electron Microscopy, South San Francisco, CA, USA
| | - Meredith Sagolla
- Genentech, Research Pathology, Center for Advanced Light and Electron Microscopy, South San Francisco, CA, USA
| | - Mike Reichelt
- Genentech, Research Pathology, Center for Advanced Light and Electron Microscopy, South San Francisco, CA, USA
| |
Collapse
|
3
|
Patil NS, Nabet BY, Müller S, Koeppen H, Zou W, Giltnane J, Au-Yeung A, Srivats S, Cheng JH, Takahashi C, de Almeida PE, Chitre AS, Grogan JL, Rangell L, Jayakar S, Peterson M, Hsia AW, O'Gorman WE, Ballinger M, Banchereau R, Shames DS. Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancer. Cancer Cell 2022; 40:289-300.e4. [PMID: 35216676 DOI: 10.1016/j.ccell.2022.02.002] [Citation(s) in RCA: 118] [Impact Index Per Article: 59.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/26/2021] [Revised: 11/11/2021] [Accepted: 02/02/2022] [Indexed: 12/15/2022]
Abstract
Inhibitors of the programmed cell death-1 (PD-1/PD-L1) signaling axis are approved to treat non-small cell lung cancer (NSCLC) patients, based on their significant overall survival (OS) benefit. Using transcriptomic analysis of 891 NSCLC tumors from patients treated with either the PD-L1 inhibitor atezolizumab or chemotherapy from two large randomized clinical trials, we find a significant B cell association with extended OS with PD-L1 blockade, independent of CD8+ T cell signals. We then derive gene signatures corresponding to the dominant B cell subsets present in NSCLC from single-cell RNA sequencing (RNA-seq) data. Importantly, we find increased plasma cell signatures to be predictive of OS in patients treated with atezolizumab, but not chemotherapy. B and plasma cells are also associated with the presence of tertiary lymphoid structures and organized lymphoid aggregates. Our results suggest an important contribution of B and plasma cells to the efficacy of PD-L1 blockade in NSCLC.
Collapse
Affiliation(s)
- Namrata S Patil
- Oncology Biomarker Development, Genentech, Inc., South San Francisco, CA, USA.
| | - Barzin Y Nabet
- Oncology Biomarker Development, Genentech, Inc., South San Francisco, CA, USA.
| | - Sören Müller
- Oncology Bioinformatics, Genentech, Inc., South San Francisco, CA, USA
| | - Hartmut Koeppen
- Research Pathology, Genentech, Inc., South San Francisco, CA, USA
| | - Wei Zou
- Oncology Biomarker Development, Genentech, Inc., South San Francisco, CA, USA
| | | | - Amelia Au-Yeung
- OMNI Biomarker Development, Genentech, Inc., South San Francisco, CA, USA
| | - Shyam Srivats
- Oncology Biomarker Development, Genentech, Inc., South San Francisco, CA, USA
| | - Jason H Cheng
- Oncology Biomarker Development, Genentech, Inc., South San Francisco, CA, USA
| | - Chikara Takahashi
- OMNI Biomarker Development, Genentech, Inc., South San Francisco, CA, USA
| | | | - Avantika S Chitre
- Cancer Immunology Research, Genentech, Inc., South San Francisco, CA, USA
| | - Jane L Grogan
- Cancer Immunology Research, Genentech, Inc., South San Francisco, CA, USA
| | - Linda Rangell
- Research Pathology, Genentech, Inc., South San Francisco, CA, USA
| | - Sangeeta Jayakar
- Research Pathology, Genentech, Inc., South San Francisco, CA, USA
| | - Maureen Peterson
- Oncology Biomarker Development, Genentech, Inc., South San Francisco, CA, USA
| | - Allison W Hsia
- Oncology Biomarker Development, Genentech, Inc., South San Francisco, CA, USA
| | - William E O'Gorman
- OMNI Biomarker Development, Genentech, Inc., South San Francisco, CA, USA
| | | | - Romain Banchereau
- Oncology Biomarker Development, Genentech, Inc., South San Francisco, CA, USA
| | - David S Shames
- Oncology Biomarker Development, Genentech, Inc., South San Francisco, CA, USA
| |
Collapse
|
4
|
Havnar C, Lau S, Hung J, Eastham-Anderson J, Espiritu C, Rangell L, Koeppen H, Ziai J, Foreman O. Characterization of Tumor-immune Microenvironment by High-throughput Image Analysis of CD8 Immunohistochemistry Combined With Modified Masson's Trichrome. J Histochem Cytochem 2021; 69:611-615. [PMID: 34353148 DOI: 10.1369/00221554211034935] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
With the advent of checkpoint inhibitors, there is increasing need to study the dynamics of CD8+ T-cells in the tumor microenviroment. In this article, we describe a semi-automated method to quantify and interrogate spatial relationships between T-cells and collagenous stroma in human and mouse tissue samples. The assay combines CD8 immunohistochemistry with modified Masson's trichrome. Slides are scanned and digital images are analyzed using an adjustable MATLAB algorithm, allowing for high-throughput quantification of cytotoxic T-cells and collagen. This method provides a flexible tool for unbiased quantification of T-cells and their interactions with tumor cells and tumor microenvironment in tissue samples.
Collapse
Affiliation(s)
- Charles Havnar
- Department of Research Pathology, Genentech, Inc., South San Francisco, California
| | - Shari Lau
- Department of Research Pathology, Genentech, Inc., South San Francisco, California
| | - Jeffrey Hung
- Department of Research Pathology, Genentech, Inc., South San Francisco, California
| | | | - Carmina Espiritu
- Department of Research Pathology, Genentech, Inc., South San Francisco, California
| | - Linda Rangell
- Department of Research Pathology, Genentech, Inc., South San Francisco, California
| | - Hartmut Koeppen
- Department of Research Pathology, Genentech, Inc., South San Francisco, California
| | - James Ziai
- Department of Research Pathology, Genentech, Inc., South San Francisco, California
| | - Oded Foreman
- Department of Research Pathology, Genentech, Inc., South San Francisco, California
| |
Collapse
|
5
|
Chan S, Filézac de L’Etang A, Rangell L, Caplazi P, Lowe JB, Romeo V. A method for manual and automated multiplex RNAscope in situ hybridization and immunocytochemistry on cytospin samples. PLoS One 2018; 13:e0207619. [PMID: 30458053 PMCID: PMC6245747 DOI: 10.1371/journal.pone.0207619] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2018] [Accepted: 11/02/2018] [Indexed: 02/01/2023] Open
Abstract
In situ analysis of biomarkers is essential for clinical diagnosis and research purposes. The increasing need to understand the molecular signature of pathologies has led to the blooming of ultrasensitive and multiplexable techniques that combine in situ hybridization (ISH) and immunohistochemistry or immunocytochemistry (IHC or ICC). Most protocols are tailored to formalin-fixed paraffin embedded (FFPE) tissue sections. However, methods to perform such assays on non-adherent cell samples, such as patient blood-derived PBMCs, rare tumor samples, effusions or other body fluids, dissociated or sorted cells, are limited. Typically, a laboratory would need to invest a significant amount of time and resources to establish one such assay. Here, we describe a method that combines ultrasensitive RNAscope-ISH with ICC on cytospin cell preparations. This method allows automated, sensitive, multiplex ISH-ICC on small numbers of non-adherent cells. We provide guidelines for both chromogenic and fluorescent ISH/ICC combinations that can be performed either in fully automated or in manual settings. By using a CD8+ T cells in vitro stimulation paradigm, we demonstrate that this protocol is sensitive enough to detect subtle differences in gene expression and compares well to commonly used methods such as RT-qPCR and flow cytometry with the added benefit of visualization at the cellular level.
Collapse
Affiliation(s)
- Sara Chan
- ISH/IHC core—Department of Pathology, Genentech Inc., South San Francisco, California, United States of America
| | - Audrey Filézac de L’Etang
- Department of Neuroscience, Genentech Inc., South San Francisco, California, United States of America
| | - Linda Rangell
- ISH/IHC core—Department of Pathology, Genentech Inc., South San Francisco, California, United States of America
| | - Patrick Caplazi
- Department of Research Pathology, Genentech Inc., South San Francisco, CA, United States of America
| | - John B. Lowe
- Department of Research Pathology, Genentech Inc., South San Francisco, CA, United States of America
| | - Valentina Romeo
- Department of Research Pathology, Genentech Inc., South San Francisco, CA, United States of America
- * E-mail:
| |
Collapse
|
6
|
Katschke KJ, Xi H, Cox C, Truong T, Malato Y, Lee WP, McKenzie B, Arceo R, Tao J, Rangell L, Reichelt M, Diehl L, Elstrott J, Weimer RM, van Lookeren Campagne M. Classical and alternative complement activation on photoreceptor outer segments drives monocyte-dependent retinal atrophy. Sci Rep 2018; 8:7348. [PMID: 29743491 PMCID: PMC5943270 DOI: 10.1038/s41598-018-25557-8] [Citation(s) in RCA: 38] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2017] [Accepted: 04/19/2018] [Indexed: 01/13/2023] Open
Abstract
Geographic atrophy (GA), the advanced form of dry age-related macular degeneration (AMD), is characterized by progressive loss of retinal pigment epithelium cells and photoreceptors in the setting of characteristic extracellular deposits and remains a serious unmet medical need. While genetic predisposition to AMD is dominated by polymorphisms in complement genes, it remains unclear how complement activation contributes to retinal atrophy. Here we demonstrate that complement is activated on photoreceptor outer segments (POS) in the retina peripheral to atrophic lesions associated with GA. When exposed to human serum following outer blood-retinal barrier breakdown, POS act as potent activators of the classical and alternative complement pathway. In mouse models of retinal degeneration, classical and alternative pathway complement activation on photoreceptors contributed to the loss of photoreceptor function. This was dependent on C5a-mediated recruitment of peripheral blood monocytes but independent of resident microglia. Genetic or pharmacologic inhibition of both classical and alternative complement C3 and C5 convertases was required to reduce progressive degeneration of photoreceptor rods and cones. Our study implicates systemic classical and alternative complement proteins and peripheral blood monocytes as critical effectors of localized retinal degeneration with potential relevance for the contribution of complement activation to GA.
Collapse
Affiliation(s)
- Kenneth J Katschke
- Department of Immunology, Genentech, Inc, South San Francisco, CA, 94080, USA
| | - Hongkang Xi
- Department of Immunology, Genentech, Inc, South San Francisco, CA, 94080, USA
| | - Christian Cox
- Department of Immunology, Genentech, Inc, South San Francisco, CA, 94080, USA
| | - Tom Truong
- Department of Translational Immunology, Genentech, Inc, South San Francisco, CA, 94080, USA
| | - Yann Malato
- Department of Translational Immunology, Genentech, Inc, South San Francisco, CA, 94080, USA
| | - Wyne P Lee
- Department of Translational Immunology, Genentech, Inc, South San Francisco, CA, 94080, USA
| | - Brent McKenzie
- Department of Translational Immunology, Genentech, Inc, South San Francisco, CA, 94080, USA
| | - Rommel Arceo
- Department of Pathology, Genentech, Inc, South San Francisco, CA, 94080, USA
| | - Jianhua Tao
- Department of Pathology, Genentech, Inc, South San Francisco, CA, 94080, USA
| | - Linda Rangell
- Department of Pathology, Genentech, Inc, South San Francisco, CA, 94080, USA
| | - Mike Reichelt
- Department of Pathology, Genentech, Inc, South San Francisco, CA, 94080, USA
| | - Lauri Diehl
- Department of Pathology, Genentech, Inc, South San Francisco, CA, 94080, USA
| | - Justin Elstrott
- Department of Biomedical Imaging, Genentech, Inc, South San Francisco, CA, 94080, USA
| | - Robby M Weimer
- Department of Biomedical Imaging, Genentech, Inc, South San Francisco, CA, 94080, USA
| | | |
Collapse
|
7
|
Salphati L, Alicke B, Heffron TP, Shahidi-Latham S, Nishimura M, Cao T, Carano RA, Cheong J, Greve J, Koeppen H, Lau S, Lee LB, Nannini-Pepe M, Pang J, Plise EG, Quiason C, Rangell L, Zhang X, Gould SE, Phillips HS, Olivero AG. Brain Distribution and Efficacy of the Brain Penetrant PI3K Inhibitor GDC-0084 in Orthotopic Mouse Models of Human Glioblastoma. Drug Metab Dispos 2016; 44:1881-1889. [PMID: 27638506 DOI: 10.1124/dmd.116.071423] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2016] [Accepted: 09/09/2016] [Indexed: 01/08/2023] Open
Abstract
Glioblastoma multiforme (GBM) is the most common primary brain tumor in adults. Limited treatment options have only marginally impacted patient survival over the past decades. The phophatidylinositol 3-kinase (PI3K) pathway, frequently altered in GBM, represents a potential target for the treatment of this glioma. 5-(6,6-Dimethyl-4-morpholino-8,9-dihydro-6H-[1,4]oxazino[4,3-e]purin-2-yl)pyrimidin-2-amine (GDC-0084) is a PI3K inhibitor that was specifically optimized to cross the blood-brain barrier. The goals of our studies were to characterize the brain distribution, pharmacodynamic (PD) effect, and efficacy of GDC-0084 in orthotopic xenograft models of GBM. GDC-0084 was tested in vitro to assess its sensitivity to the efflux transporters P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) and in vivo in mice to evaluate its effects on the PI3K pathway in intact brain. Mice bearing U87 or GS2 intracranial tumors were treated with GDC-0084 to assess its brain distribution by matrix-assisted laser desorption ionization (MALDI) imaging and measure its PD effects and efficacy in GBM orthotopic models. Studies in transfected cells indicated that GDC-0084 was not a substrate of P-gp or BCRP. GDC-0084 markedly inhibited the PI3K pathway in mouse brain, causing up to 90% suppression of the pAkt signal. MALDI imaging showed GDC-0084 distributed evenly in brain and intracranial U87 and GS2 tumors. GDC-0084 achieved significant tumor growth inhibition of 70% and 40% against the U87 and GS2 orthotopic models, respectively. GDC-0084 distribution throughout the brain and intracranial tumors led to potent inhibition of the PI3K pathway. Its efficacy in orthotopic models of GBM suggests that it could be effective in the treatment of GBM. GDC-0084 is currently in phase I clinical trials.
Collapse
Affiliation(s)
- Laurent Salphati
- Departments of Drug Metabolism and Pharmacokinetics (L.S., S.S.-L., J.C., J.P., E.G.P., C.Q., X.Z.), Discovery Chemistry (T.P.H., A.G.O.), Cancer Signaling and Translational Oncology (B.A., M.N., M.N.-P., L.B.L., S.E.G., H.S.P.), Biomedical Imaging (T.C., R.A.C., J.G.), and Pathology (H.K., S.L., L.R.), Genentech Inc., South San Francisco, California
| | - Bruno Alicke
- Departments of Drug Metabolism and Pharmacokinetics (L.S., S.S.-L., J.C., J.P., E.G.P., C.Q., X.Z.), Discovery Chemistry (T.P.H., A.G.O.), Cancer Signaling and Translational Oncology (B.A., M.N., M.N.-P., L.B.L., S.E.G., H.S.P.), Biomedical Imaging (T.C., R.A.C., J.G.), and Pathology (H.K., S.L., L.R.), Genentech Inc., South San Francisco, California
| | - Timothy P Heffron
- Departments of Drug Metabolism and Pharmacokinetics (L.S., S.S.-L., J.C., J.P., E.G.P., C.Q., X.Z.), Discovery Chemistry (T.P.H., A.G.O.), Cancer Signaling and Translational Oncology (B.A., M.N., M.N.-P., L.B.L., S.E.G., H.S.P.), Biomedical Imaging (T.C., R.A.C., J.G.), and Pathology (H.K., S.L., L.R.), Genentech Inc., South San Francisco, California
| | - Sheerin Shahidi-Latham
- Departments of Drug Metabolism and Pharmacokinetics (L.S., S.S.-L., J.C., J.P., E.G.P., C.Q., X.Z.), Discovery Chemistry (T.P.H., A.G.O.), Cancer Signaling and Translational Oncology (B.A., M.N., M.N.-P., L.B.L., S.E.G., H.S.P.), Biomedical Imaging (T.C., R.A.C., J.G.), and Pathology (H.K., S.L., L.R.), Genentech Inc., South San Francisco, California
| | - Merry Nishimura
- Departments of Drug Metabolism and Pharmacokinetics (L.S., S.S.-L., J.C., J.P., E.G.P., C.Q., X.Z.), Discovery Chemistry (T.P.H., A.G.O.), Cancer Signaling and Translational Oncology (B.A., M.N., M.N.-P., L.B.L., S.E.G., H.S.P.), Biomedical Imaging (T.C., R.A.C., J.G.), and Pathology (H.K., S.L., L.R.), Genentech Inc., South San Francisco, California
| | - Tim Cao
- Departments of Drug Metabolism and Pharmacokinetics (L.S., S.S.-L., J.C., J.P., E.G.P., C.Q., X.Z.), Discovery Chemistry (T.P.H., A.G.O.), Cancer Signaling and Translational Oncology (B.A., M.N., M.N.-P., L.B.L., S.E.G., H.S.P.), Biomedical Imaging (T.C., R.A.C., J.G.), and Pathology (H.K., S.L., L.R.), Genentech Inc., South San Francisco, California
| | - Richard A Carano
- Departments of Drug Metabolism and Pharmacokinetics (L.S., S.S.-L., J.C., J.P., E.G.P., C.Q., X.Z.), Discovery Chemistry (T.P.H., A.G.O.), Cancer Signaling and Translational Oncology (B.A., M.N., M.N.-P., L.B.L., S.E.G., H.S.P.), Biomedical Imaging (T.C., R.A.C., J.G.), and Pathology (H.K., S.L., L.R.), Genentech Inc., South San Francisco, California
| | - Jonathan Cheong
- Departments of Drug Metabolism and Pharmacokinetics (L.S., S.S.-L., J.C., J.P., E.G.P., C.Q., X.Z.), Discovery Chemistry (T.P.H., A.G.O.), Cancer Signaling and Translational Oncology (B.A., M.N., M.N.-P., L.B.L., S.E.G., H.S.P.), Biomedical Imaging (T.C., R.A.C., J.G.), and Pathology (H.K., S.L., L.R.), Genentech Inc., South San Francisco, California
| | - Joan Greve
- Departments of Drug Metabolism and Pharmacokinetics (L.S., S.S.-L., J.C., J.P., E.G.P., C.Q., X.Z.), Discovery Chemistry (T.P.H., A.G.O.), Cancer Signaling and Translational Oncology (B.A., M.N., M.N.-P., L.B.L., S.E.G., H.S.P.), Biomedical Imaging (T.C., R.A.C., J.G.), and Pathology (H.K., S.L., L.R.), Genentech Inc., South San Francisco, California
| | - Hartmut Koeppen
- Departments of Drug Metabolism and Pharmacokinetics (L.S., S.S.-L., J.C., J.P., E.G.P., C.Q., X.Z.), Discovery Chemistry (T.P.H., A.G.O.), Cancer Signaling and Translational Oncology (B.A., M.N., M.N.-P., L.B.L., S.E.G., H.S.P.), Biomedical Imaging (T.C., R.A.C., J.G.), and Pathology (H.K., S.L., L.R.), Genentech Inc., South San Francisco, California
| | - Shari Lau
- Departments of Drug Metabolism and Pharmacokinetics (L.S., S.S.-L., J.C., J.P., E.G.P., C.Q., X.Z.), Discovery Chemistry (T.P.H., A.G.O.), Cancer Signaling and Translational Oncology (B.A., M.N., M.N.-P., L.B.L., S.E.G., H.S.P.), Biomedical Imaging (T.C., R.A.C., J.G.), and Pathology (H.K., S.L., L.R.), Genentech Inc., South San Francisco, California
| | - Leslie B Lee
- Departments of Drug Metabolism and Pharmacokinetics (L.S., S.S.-L., J.C., J.P., E.G.P., C.Q., X.Z.), Discovery Chemistry (T.P.H., A.G.O.), Cancer Signaling and Translational Oncology (B.A., M.N., M.N.-P., L.B.L., S.E.G., H.S.P.), Biomedical Imaging (T.C., R.A.C., J.G.), and Pathology (H.K., S.L., L.R.), Genentech Inc., South San Francisco, California
| | - Michelle Nannini-Pepe
- Departments of Drug Metabolism and Pharmacokinetics (L.S., S.S.-L., J.C., J.P., E.G.P., C.Q., X.Z.), Discovery Chemistry (T.P.H., A.G.O.), Cancer Signaling and Translational Oncology (B.A., M.N., M.N.-P., L.B.L., S.E.G., H.S.P.), Biomedical Imaging (T.C., R.A.C., J.G.), and Pathology (H.K., S.L., L.R.), Genentech Inc., South San Francisco, California
| | - Jodie Pang
- Departments of Drug Metabolism and Pharmacokinetics (L.S., S.S.-L., J.C., J.P., E.G.P., C.Q., X.Z.), Discovery Chemistry (T.P.H., A.G.O.), Cancer Signaling and Translational Oncology (B.A., M.N., M.N.-P., L.B.L., S.E.G., H.S.P.), Biomedical Imaging (T.C., R.A.C., J.G.), and Pathology (H.K., S.L., L.R.), Genentech Inc., South San Francisco, California
| | - Emile G Plise
- Departments of Drug Metabolism and Pharmacokinetics (L.S., S.S.-L., J.C., J.P., E.G.P., C.Q., X.Z.), Discovery Chemistry (T.P.H., A.G.O.), Cancer Signaling and Translational Oncology (B.A., M.N., M.N.-P., L.B.L., S.E.G., H.S.P.), Biomedical Imaging (T.C., R.A.C., J.G.), and Pathology (H.K., S.L., L.R.), Genentech Inc., South San Francisco, California
| | - Cristine Quiason
- Departments of Drug Metabolism and Pharmacokinetics (L.S., S.S.-L., J.C., J.P., E.G.P., C.Q., X.Z.), Discovery Chemistry (T.P.H., A.G.O.), Cancer Signaling and Translational Oncology (B.A., M.N., M.N.-P., L.B.L., S.E.G., H.S.P.), Biomedical Imaging (T.C., R.A.C., J.G.), and Pathology (H.K., S.L., L.R.), Genentech Inc., South San Francisco, California
| | - Linda Rangell
- Departments of Drug Metabolism and Pharmacokinetics (L.S., S.S.-L., J.C., J.P., E.G.P., C.Q., X.Z.), Discovery Chemistry (T.P.H., A.G.O.), Cancer Signaling and Translational Oncology (B.A., M.N., M.N.-P., L.B.L., S.E.G., H.S.P.), Biomedical Imaging (T.C., R.A.C., J.G.), and Pathology (H.K., S.L., L.R.), Genentech Inc., South San Francisco, California
| | - Xiaolin Zhang
- Departments of Drug Metabolism and Pharmacokinetics (L.S., S.S.-L., J.C., J.P., E.G.P., C.Q., X.Z.), Discovery Chemistry (T.P.H., A.G.O.), Cancer Signaling and Translational Oncology (B.A., M.N., M.N.-P., L.B.L., S.E.G., H.S.P.), Biomedical Imaging (T.C., R.A.C., J.G.), and Pathology (H.K., S.L., L.R.), Genentech Inc., South San Francisco, California
| | - Stephen E Gould
- Departments of Drug Metabolism and Pharmacokinetics (L.S., S.S.-L., J.C., J.P., E.G.P., C.Q., X.Z.), Discovery Chemistry (T.P.H., A.G.O.), Cancer Signaling and Translational Oncology (B.A., M.N., M.N.-P., L.B.L., S.E.G., H.S.P.), Biomedical Imaging (T.C., R.A.C., J.G.), and Pathology (H.K., S.L., L.R.), Genentech Inc., South San Francisco, California
| | - Heidi S Phillips
- Departments of Drug Metabolism and Pharmacokinetics (L.S., S.S.-L., J.C., J.P., E.G.P., C.Q., X.Z.), Discovery Chemistry (T.P.H., A.G.O.), Cancer Signaling and Translational Oncology (B.A., M.N., M.N.-P., L.B.L., S.E.G., H.S.P.), Biomedical Imaging (T.C., R.A.C., J.G.), and Pathology (H.K., S.L., L.R.), Genentech Inc., South San Francisco, California
| | - Alan G Olivero
- Departments of Drug Metabolism and Pharmacokinetics (L.S., S.S.-L., J.C., J.P., E.G.P., C.Q., X.Z.), Discovery Chemistry (T.P.H., A.G.O.), Cancer Signaling and Translational Oncology (B.A., M.N., M.N.-P., L.B.L., S.E.G., H.S.P.), Biomedical Imaging (T.C., R.A.C., J.G.), and Pathology (H.K., S.L., L.R.), Genentech Inc., South San Francisco, California
| |
Collapse
|
8
|
Rajapaksa KS, Huang T, Sharma N, Liu S, Solon M, Reyes A, Paul S, Yee A, Tao J, Chalasani S, Bien-Ly N, Barck K, Carano RAD, Wang J, Rangell L, Bremer M, Danilenko DM, Katavolos P, Hotzel I, Reif K, Austin CD. Preclinical Safety Profile of a Depleting Antibody against CRTh2 for Asthma: Well Tolerated Despite Unexpected CRTh2 Expression on Vascular Pericytes in the Central Nervous System and Gastric Mucosa. Toxicol Sci 2016; 152:72-84. [PMID: 27103662 DOI: 10.1093/toxsci/kfw067] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
CRTh2 is expressed on immune cells that drive asthma pathophysiology. Current treatment options for severe asthma are inadequate and therapeutic antibody-mediated depletion of CRTh2-expressing cells represents a promising new therapeutic strategy. Here we report for the first time that CRTh2 is not only expressed on immune cells, but also on microvasculature in the central nervous system (CNS) and gastric mucosa in humans. Microvascular expression of CRTh2 raises a safety concern because a therapeutic antiCRTh2 antibody with enhanced depletion capacity could lead to vascular damage. To evaluate this safety risk, we characterized microvascular expression in human and in transgenic mice expressing human CRTh2 protein (hCRTh2.BAC.Tg) and found that CRTh2 is not localized to microvascular endothelium that is directly exposed to circulating therapeutic antibody, but rather, to pericytes that in the CNS are shielded from direct circulatory exposure by the blood-brain barrier. Immunohistochemical visualization of an intravenously administered antiCRTh2 antibody in transgenic mice revealed localization to microvascular pericytes in the gastric mucosa but not in the CNS, suggesting the blood-brain barrier effectively limits pericyte exposure to circulating therapeutic antibody in the CNS. Repeated dosing with a depleting antiCRTh2 antibody in hCRTh2.BAC.Tg mice revealed linear pharmacokinetics and no drug-related adverse findings in any tissues, including the CNS and gastric mucosa, despite complete depletion of CRTh2 expressing circulating eosinophils and basophils. Collectively, these studies demonstrate that the likelihood of drug-related CNS or gastrointestinal toxicity in humans treated with a therapeutic depleting antiCRTh2 antibody is low despite pericyte expression of CRTh2 in these tissues.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | - Meire Bremer
- OMNI Biomarker Development, Genentech Inc, South San Francisco, California, 94080
| | | | | | | | - Karin Reif
- Immunology Preclinical and Translational Pharmacokinetics
| | | |
Collapse
|
9
|
Zhou Y, Liu P, Gan Y, Sandoval W, Katakam AK, Reichelt M, Rangell L, Reilly D. Enhancing full-length antibody production by signal peptide engineering. Microb Cell Fact 2016; 15:47. [PMID: 26935575 PMCID: PMC4776426 DOI: 10.1186/s12934-016-0445-3] [Citation(s) in RCA: 36] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2015] [Accepted: 02/21/2016] [Indexed: 11/24/2022] Open
Abstract
Background Protein secretion to the periplasm of Escherichia coli offers an attractive route for producing heterologous proteins including antibodies. In this approach, a signal peptide is fused to the N-terminus of the heterologous protein. The signal peptide mediates translocation of the heterologous protein from the cytoplasm to the periplasm and is cleaved during the translocation process. It was previously shown that optimization of the translation initiation region (TIR) which overlaps with the nucleotide sequence of the signal sequence improves the production of heterologous proteins. Despite the progress, there is still room to improve yields using secretion as a means to produce protein complexes such as full-length monoclonal antibodies (mAbs). Results In this study we identified the inefficient secretion of heavy chain as the limitation for full-length mAb accumulation in the periplasm. To improve heavy chain secretion we investigated the effects of various signal peptides at controlled TIR strengths. The signal peptide of disulfide oxidoreductase (DsbA) mediated more efficient secretion of heavy chain than the other signal peptides tested. Mutagenesis studies demonstrated that at controlled translational levels, hydrophobicity of the hydrophobic core (H-region) of the signal peptide is a critical factor for heavy chain secretion and full-length mAb accumulation in the periplasm. Increasing the hydrophobicity of a signal peptide enhanced heavy chain secretion and periplasmic levels of assembled full-length mAbs, while decreasing the hydrophobicity had the opposite effect. Conclusions This study demonstrates that under similar translational strengths, the hydrophobicity of the signal peptide plays an important role in heavy chain secretion. Increasing the hydrophobicity of the H-region and controlling TIR strengths can serve as an approach to improve heavy chain secretion and full-length mAb production in E. coli. Electronic supplementary material The online version of this article (doi:10.1186/s12934-016-0445-3) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Yizhou Zhou
- Department of Early Stage Cell Culture, Genentech Inc., 1 DNA way, South San Francisco, CA, 94080, USA.
| | - Peter Liu
- Department of Protein Chemistry, Genentech Inc., 1 DNA way, South San Francisco, CA, 94080, USA.
| | - Yutian Gan
- Department of Protein Chemistry, Genentech Inc., 1 DNA way, South San Francisco, CA, 94080, USA.
| | - Wendy Sandoval
- Department of Protein Chemistry, Genentech Inc., 1 DNA way, South San Francisco, CA, 94080, USA.
| | - Anand Kumar Katakam
- Department of Pathology, Genentech Inc., 1 DNA way, South San Francisco, CA, 94080, USA.
| | - Mike Reichelt
- Department of Pathology, Genentech Inc., 1 DNA way, South San Francisco, CA, 94080, USA.
| | - Linda Rangell
- Department of Pathology, Genentech Inc., 1 DNA way, South San Francisco, CA, 94080, USA.
| | - Dorothea Reilly
- Department of Early Stage Cell Culture, Genentech Inc., 1 DNA way, South San Francisco, CA, 94080, USA.
| |
Collapse
|
10
|
Xi H, Katschke KJ, Li Y, Truong T, Lee WP, Diehl L, Rangell L, Tao J, Arceo R, Eastham-Anderson J, Hackney JA, Iglesias A, Cote-Sierra J, Elstrott J, Weimer RM, van Lookeren Campagne M. IL-33 amplifies an innate immune response in the degenerating retina. J Exp Med 2016; 213:189-207. [PMID: 26755704 PMCID: PMC4749925 DOI: 10.1084/jem.20150894] [Citation(s) in RCA: 54] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/28/2015] [Accepted: 12/07/2015] [Indexed: 01/12/2023] Open
Abstract
Xi et al. demonstrate that IL-33 is a key regulator of retinal inflammation and degeneration. Age-related macular degeneration (AMD), a leading cause of vision impairment in the ageing population, is characterized by irreversible loss of retinal pigment epithelial (RPE) cells and photoreceptors and can be associated with choroidal neovascularization. Mononuclear phagocytes are often present in AMD lesions, but the processes that direct myeloid cell recruitment remain unclear. Here, we identify IL-33 as a key regulator of inflammation and photoreceptor degeneration after retina stress or injury. IL-33+ Müller cells were more abundant and IL-33 cytokine was elevated in advanced AMD cases compared with age-matched controls with no AMD. In rodents, retina stress resulted in release of bioactive IL-33 that in turn increased inflammatory chemokine and cytokine expression in activated Müller cells. Deletion of ST2, the IL-33 receptor α chain, or treatment with a soluble IL-33 decoy receptor significantly reduced release of inflammatory mediators from Müller cells, inhibited accumulation of mononuclear phagocytes in the outer retina, and protected photoreceptor rods and cones after a retina insult. This study demonstrates a central role for IL-33 in regulating mononuclear phagocyte recruitment to the photoreceptor layer and positions IL-33 signaling as a potential therapeutic target in macular degenerative diseases.
Collapse
Affiliation(s)
- Hongkang Xi
- Department of Immunology, Genentech, Inc., South San Francisco, CA 94080
| | - Kenneth J Katschke
- Department of Immunology, Genentech, Inc., South San Francisco, CA 94080
| | - Yun Li
- Department of Immunology, Genentech, Inc., South San Francisco, CA 94080
| | - Tom Truong
- Department of Immunology, Genentech, Inc., South San Francisco, CA 94080
| | - Wyne P Lee
- Department of Immunology, Genentech, Inc., South San Francisco, CA 94080
| | - Lauri Diehl
- Department of Pathology, Genentech, Inc., South San Francisco, CA 94080
| | - Linda Rangell
- Department of Pathology, Genentech, Inc., South San Francisco, CA 94080
| | - Jianhua Tao
- Department of Pathology, Genentech, Inc., South San Francisco, CA 94080
| | - Rommel Arceo
- Department of Pathology, Genentech, Inc., South San Francisco, CA 94080
| | | | - Jason A Hackney
- Department of Bioinformatics and Computational Biology, Genentech, Inc., South San Francisco, CA 94080
| | - Antonio Iglesias
- Roche Pharmaceutical Research and Early Development, Pharmacological Sciences, Roche Innovation Center Basel, CH-4070 Basel, Switzerland
| | - Javier Cote-Sierra
- Roche Pharmaceutical Research and Early Development, Pharmacological Sciences, Roche Innovation Center Basel, CH-4070 Basel, Switzerland
| | - Justin Elstrott
- Department of Biomedical Imaging, Genentech, Inc., South San Francisco, CA 94080
| | - Robby M Weimer
- Department of Biomedical Imaging, Genentech, Inc., South San Francisco, CA 94080
| | | |
Collapse
|
11
|
Del Nagro C, Xiao Y, Rangell L, Reichelt M, O'Brien T. Depletion of the central metabolite NAD leads to oncosis-mediated cell death. J Biol Chem 2014; 289:35182-92. [PMID: 25355314 DOI: 10.1074/jbc.m114.580159] [Citation(s) in RCA: 58] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022] Open
Abstract
Depletion of the central metabolite NAD in cells results in broad metabolic defects leading to cell death and is a proposed novel therapeutic strategy in oncology. There is, however, a limited understanding of the underlying mechanisms that connect disruption of this central metabolite with cell death. Here we utilize GNE-617, a small molecule inhibitor of NAMPT, a rate-limiting enzyme required for NAD generation, to probe the pathways leading to cell death following NAD depletion. In all cell lines examined, NAD was rapidly depleted (average t½ of 8.1 h) following NAMPT inhibition. Concurrent with NAD depletion, there was a decrease in both cell proliferation and motility, which we attribute to reduced activity of NAD-dependent deacetylases because cells fail to deacetylate α-tubulin-K40 and histone H3-K9. Following depletion of NAD by >95%, cells lose the ability to regenerate ATP. Cell lines with a slower rate of ATP depletion (average t½ of 45 h) activate caspase-3 and show evidence of apoptosis and autophagy, whereas cell lines with rapid depletion ATP (average t½ of 32 h) do not activate caspase-3 or show signs of apoptosis or autophagy. However, the predominant form of cell death in all lines is oncosis, which is driven by the loss of plasma membrane homeostasis once ATP levels are depleted by >20-fold. Thus, our work illustrates the sequence of events that occurs in cells following depletion of a key metabolite and reveals that cell death caused by a loss of NAD is primarily driven by the inability of cells to regenerate ATP.
Collapse
Affiliation(s)
| | - Yang Xiao
- From the Departments of Translational Oncology and
| | - Linda Rangell
- Pathology, Genentech Inc., South San Francisco, California 94080
| | - Mike Reichelt
- Pathology, Genentech Inc., South San Francisco, California 94080
| | | |
Collapse
|
12
|
Scales SJ, Gupta N, Pacheco G, Firestein R, French DM, Koeppen H, Rangell L, Barry-Hamilton V, Luis E, Chuh J, Zhang Y, Ingle GS, Fourie-O'Donohue A, Kozak KR, Ross S, Dennis MS, Spencer SD. An antimesothelin-monomethyl auristatin e conjugate with potent antitumor activity in ovarian, pancreatic, and mesothelioma models. Mol Cancer Ther 2014; 13:2630-40. [PMID: 25249555 DOI: 10.1158/1535-7163.mct-14-0487-t] [Citation(s) in RCA: 47] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Mesothelin (MSLN) is an attractive target for antibody-drug conjugate therapy because it is highly expressed in various epithelial cancers, with normal expression limited to nondividing mesothelia. We generated novel antimesothelin antibodies and conjugated an internalizing one (7D9) to the microtubule-disrupting drugs monomethyl auristatin E (MMAE) and MMAF, finding the most effective to be MMAE with a lysosomal protease-cleavable valine-citrulline linker. The humanized (h7D9.v3) version, αMSLN-MMAE, specifically targeted mesothelin-expressing cells and inhibited their proliferation with an IC50 of 0.3 nmol/L. Because the antitumor activity of an antimesothelin immunotoxin (SS1P) in transfected mesothelin models did not translate to the clinic, we carefully selected in vivo efficacy models endogenously expressing clinically relevant levels of mesothelin, after scoring mesothelin levels in ovarian, pancreatic, and mesothelioma tumors by immunohistochemistry. We found that endogenous mesothelin in cancer cells is upregulated in vivo and identified two suitable xenograft models for each of these three indications. A single dose of αMSLN-MMAE profoundly inhibited or regressed tumor growth in a dose-dependent manner in all six models, including two patient-derived tumor xenografts. The robust and durable efficacy of αMSLN-MMAE in preclinical models of ovarian, mesothelioma, and pancreatic cancers justifies the ongoing phase I clinical trial.
Collapse
Affiliation(s)
- Suzie J Scales
- Department of Molecular Biology, Genentech, South San Francisco, California.
| | - Nidhi Gupta
- Department of Molecular Biology, Genentech, South San Francisco, California
| | - Glenn Pacheco
- Department of Translational Oncology, Genentech, South San Francisco, California
| | - Ron Firestein
- Department of Pathology, Genentech, South San Francisco, California
| | - Dorothy M French
- Department of Pathology, Genentech, South San Francisco, California
| | - Hartmut Koeppen
- Department of Pathology, Genentech, South San Francisco, California
| | - Linda Rangell
- Department of Pathology, Genentech, South San Francisco, California
| | | | - Elizabeth Luis
- Department of Protein Chemistry, Genentech, South San Francisco, California
| | - Josefa Chuh
- Department of Biochemical and Cellular Pharmacology, Genentech, South San Francisco, California
| | - Yin Zhang
- Department of Antibody Engineering, Genentech, South San Francisco, California
| | - Gladys S Ingle
- Department of Molecular Biology, Genentech, South San Francisco, California
| | - Aimee Fourie-O'Donohue
- Department of Biochemical and Cellular Pharmacology, Genentech, South San Francisco, California
| | - Katherine R Kozak
- Department of Biochemical and Cellular Pharmacology, Genentech, South San Francisco, California
| | - Sarajane Ross
- Department of Translational Oncology, Genentech, South San Francisco, California
| | - Mark S Dennis
- Department of Antibody Engineering, Genentech, South San Francisco, California
| | - Susan D Spencer
- Department of Translational Oncology, Genentech, South San Francisco, California
| |
Collapse
|
13
|
Shih VFS, Cox J, Kljavin NM, Dengler HS, Reichelt M, Kumar P, Rangell L, Kolls JK, Diehl L, Ouyang W, Ghilardi N. Homeostatic IL-23 receptor signaling limits Th17 response through IL-22-mediated containment of commensal microbiota. Proc Natl Acad Sci U S A 2014; 111:13942-7. [PMID: 25201978 PMCID: PMC4183330 DOI: 10.1073/pnas.1323852111] [Citation(s) in RCA: 78] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
Mammalian hosts are colonized with commensal microbes in various mucosal and epithelial tissues, including the intestinal tract. In mice, the presence of segmented filamentous bacteria (SFB) promotes Th17 differentiation and the development of autoimmune disease. Here, we demonstrate that the IL-23 pathway dynamically regulates the abundance of SFB as well as mucosal barrier function in the adult animal. Genetic or pharmacological inactivation of the pathway selectively perturbs the abundance of a small group of commensals, including SFB, and results in an impaired mucosal barrier. Defective barrier function leads to systemic dissemination of microbial products, provoking induction of the IL-23 pathway with dual consequences: IL-23 drives IL-22 production to reinforce mucosal barrier function and elicit antimicrobial activities, and it also drives the differentiation of Th17 cells in an attempt to combat escaped microbes in the lamina propria and in distal tissues. Thus, barrier defects generate a systemic environment that facilitates Th17 development.
Collapse
Affiliation(s)
| | | | | | | | - Mike Reichelt
- Pathology, Genentech, Inc., South San Francisco, CA 94080; and
| | - Pawan Kumar
- Department of Pediatrics, Children's Hospital of Pittsburgh of UPMC, University of Pittsburgh, Pittsburgh, PA 15213
| | - Linda Rangell
- Pathology, Genentech, Inc., South San Francisco, CA 94080; and
| | - Jay K Kolls
- Department of Pediatrics, Children's Hospital of Pittsburgh of UPMC, University of Pittsburgh, Pittsburgh, PA 15213
| | - Lauri Diehl
- Pathology, Genentech, Inc., South San Francisco, CA 94080; and
| | | | | |
Collapse
|
14
|
Koeppen H, Yu W, Zha J, Pandita A, Penuel E, Rangell L, Raja R, Mohan S, Patel R, Desai R, Fu L, Do A, Parab V, Xia X, Januario T, Louie SG, Filvaroff E, Shames DS, Wistuba I, Lipkind M, Huang J, Lazarov M, Ramakrishnan V, Amler L, Phan SC, Patel P, Peterson A, Yauch RL. Biomarker analyses from a placebo-controlled phase II study evaluating erlotinib±onartuzumab in advanced non-small cell lung cancer: MET expression levels are predictive of patient benefit. Clin Cancer Res 2014; 20:4488-98. [PMID: 24687921 DOI: 10.1158/1078-0432.ccr-13-1836] [Citation(s) in RCA: 110] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
PURPOSE In a recent phase II study of onartuzumab (MetMAb), patients whose non-small cell lung cancer (NSCLC) tissue scored as positive for MET protein by immunohistochemistry (IHC) experienced a significant benefit with onartuzumab plus erlotinib (O+E) versus erlotinib. We describe development and validation of a standardized MET IHC assay and, retrospectively, evaluate multiple biomarkers as predictors of patient benefit. EXPERIMENTAL DESIGN Biomarkers related to MET and/or EGF receptor (EGFR) signaling were measured by IHC, FISH, quantitative reverse transcription PCR, mutation detection techniques, and ELISA. RESULTS A positive correlation between IHC, Western blotting, and MET mRNA expression was observed in NSCLC cell lines/tissues. An IHC scoring system of MET expression taking proportional and intensity-based thresholds into consideration was applied in an analysis of the phase II study and resulted in the best differentiation of outcomes. Further analyses revealed a nonsignificant overall survival (OS) improvement with O+E in patients with high MET copy number (mean≥5 copies/cell by FISH); however, benefit was maintained in "MET IHC-positive"/MET FISH-negative patients (HR, 0.37; P=0.01). MET, EGFR, amphiregulin, epiregulin, or HGF mRNA expression did not predict a significant benefit with onartuzumab; a nonsignificant OS improvement was observed in patients with high tumor MET mRNA levels (HR, 0.59; P=0.23). Patients with low baseline plasma hepatocyte growth factor (HGF) exhibited an HR for OS of 0.519 (P=0.09) in favor of onartuzumab treatment. CONCLUSIONS MET IHC remains the most robust predictor of OS and progression-free survival benefit from O+E relative to all examined exploratory markers.
Collapse
Affiliation(s)
| | - Wei Yu
- Genentech Inc., South San Francisco
| | - Jiping Zha
- Crown Bioscience Inc., Jiangsu Province, China
| | | | | | | | | | | | | | | | - Ling Fu
- Genentech Inc., South San Francisco
| | - An Do
- Genentech Inc., South San Francisco
| | | | | | | | | | | | | | - Ignacio Wistuba
- Department of Translational Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas; and
| | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
O'Brien T, Del Nagro C, Xiao Y, Oeh J, Rangell L, Reichelt M, Liang X, Liederer BM, Dragovich PS, Sampath D. Abstract C150: Depletion of cellular NAD using the NAMPT inhibitor GNE-617 leads to oncosis blister cell death. Mol Cancer Ther 2013. [DOI: 10.1158/1535-7163.targ-13-c150] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Nicotinamide adenine dinucleotide (NAD) is a critical cellular metabolite and the key enzyme in the NAD salvage pathway is nicotinamide phosphoribosyl transferase (NAMPT). Here we describe GNE-617, a novel orally bioavailable NAMPT inhibitor, and show that this compound promotes rapid depletion of NAD both in cells and in xenograft tumor models. Moreover, GNE-617 rapidly induced tumor regressions in colorectal (HCT-116), fibrosarcoma (HT-1080), prostate (PC3) and pancreatic (MiaPaca2) xenograft models. Despite increasing interest in exploiting cancer cell metabolism as a therapeutic strategy, there is still a poor understanding of cell death mechanisms following disruption of key metabolic processes. Here we show that depletion of NAD in cells induces a series of cellular events that leads to oncosis-Blister Cell Death (oncosis-BCD). In all cell lines examined, NAD was depleted >95% within 25-39 hours, which was rapidly followed by a loss of ATP (>95% depleted by 41-76 hours). Depletion of NAD correlates with loss of cell motility and a reduction in mitotic index, which may be explained by reduced activity of NAD-dependent protein deacetylases. In support of this, we find that α-tubulin-K40 is hyper-acetylation, a modification that is known to reduce tubulin dynamics and cell motility. Additionally, there is no evidence of histone H3-K9 deacetylation, which normally occurs as cells enter mitosis. Using a combination of approaches including live cell imaging and electron microscopy we found that cell lines with a more rapid depletion of ATP display signs of necrosis and oncosis-BCD, while cell lines with a slower depletion of ATP show signs of autophagy, apoptosis, necrosis and oncosis-BCD. In all cases however, oncosis-BCD is the predominant form of cell death and is characterized by plasma membrane swelling to form large organelle-free blisters. Finally, we conclude that cell death is due to loss of plasma membrane ion-homeostasis associated with ATP depletion. In conclusion, our data shows that there is an ordered progression of events that occurs in cancer cells following NAD depletion and reveals that oncosis-BCD is the predominant form of cell death in response to NAD depletion.
Citation Information: Mol Cancer Ther 2013;12(11 Suppl):C150.
Citation Format: Thomas O'Brien, Christopher Del Nagro, Yang Xiao, Jason Oeh, Linda Rangell, Mike Reichelt, Xiaorong Liang, Bianca M. Liederer, Peter S. Dragovich, Deepak Sampath. Depletion of cellular NAD using the NAMPT inhibitor GNE-617 leads to oncosis blister cell death. [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2013 Oct 19-23; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2013;12(11 Suppl):Abstract nr C150.
Collapse
|
16
|
Shih VFS, Cox J, Kljavin N, Rardin H, Reichelt M, Rangell L, Diehl L, Ouyang W, Ghilardi N. 238. Cytokine 2013. [DOI: 10.1016/j.cyto.2013.06.241] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
17
|
Mukhopadhyay S, Wen X, Ratti N, Loktev A, Rangell L, Scales SJ, Jackson PK. The ciliary G-protein-coupled receptor Gpr161 negatively regulates the Sonic hedgehog pathway via cAMP signaling. Cell 2013; 152:210-23. [PMID: 23332756 DOI: 10.1016/j.cell.2012.12.026] [Citation(s) in RCA: 336] [Impact Index Per Article: 30.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2012] [Revised: 10/23/2012] [Accepted: 12/18/2012] [Indexed: 11/25/2022]
Abstract
The primary cilium is required for Sonic hedgehog (Shh) signaling in vertebrates. In contrast to mutants affecting ciliary assembly, mutations in the intraflagellar transport complex A (IFT-A) paradoxically cause increased Shh signaling. We previously showed that the IFT-A complex, in addition to its canonical role in retrograde IFT, binds to the tubby-like protein, Tulp3, and recruits it to cilia. Here, we describe a conserved vertebrate G-protein-coupled receptor, Gpr161, which localizes to primary cilia in a Tulp3/IFT-A-dependent manner. Complete loss of Gpr161 in mouse causes midgestation lethality and increased Shh signaling in the neural tube, phenocopying Tulp3/IFT-A mutants. Constitutive Gpr161 activity increases cAMP levels and represses Shh signaling by determining the processing of Gli3 to its repressor form. Conversely, Shh signaling directs Gpr161 to be internalized from cilia, preventing its activity. Thus, Gpr161 defines a morphogenetic pathway coupling protein kinase A activation to Shh signaling during neural tube development.
Collapse
Affiliation(s)
- Saikat Mukhopadhyay
- Department of Research Oncology, Genentech Inc., South San Francisco, CA 94080, USA.
| | | | | | | | | | | | | |
Collapse
|
18
|
Del Nagro CJ, Choi J, Xiao Y, Rangell L, Mohan S, Pandita A, Zha J, Jackson PK, O'Brien T. Chk1 inhibition in p53-deficient cell lines drives rapid chromosome fragmentation followed by caspase-independent cell death. Cell Cycle 2013; 13:303-14. [PMID: 24247149 PMCID: PMC3906246 DOI: 10.4161/cc.27055] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/15/2023] Open
Abstract
Activation of Checkpoint kinase 1 (Chk1) following DNA damage mediates cell cycle arrest to prevent cells with damaged DNA from entering mitosis. Here we provide a high-resolution analysis of cells as they undergo S- and G₂-checkpoint bypass in response to Chk1 inhibition with the selective Chk1 inhibitor GNE-783. Within 4-8 h of Chk1 inhibition following gemcitabine induced DNA damage, cells with both sub-4N and 4N DNA content prematurely enter mitosis. Coincident with premature transition into mitosis, levels of DNA damage dramatically increase and chromosomes condense and attempt to align along the metaphase plate. Despite an attempt to congress at the metaphase plate, chromosomes rapidly fragment and lose connection to the spindle microtubules. Gemcitabine mediated DNA damage promotes the formation of Rad51 foci; however, while Chk1 inhibition does not disrupt Rad51 foci that are formed in response to gemcitabine, these foci are lost as cells progress into mitosis. Premature entry into mitosis requires the Aurora, Cdk1/2 and Plk1 kinases and even though caspase-2 and -3 are activated upon mitotic exit, they are not required for cell death. Interestingly, p53, but not p21, deficiency enables checkpoint bypass and chemo-potentiation. Finally, we uncover a differential role for the Wee-1 checkpoint kinase in response to DNA damage, as Wee-1, but not Chk1, plays a more prominent role in the maintenance of S- and G₂-checkpoints in p53 proficient cells.
Collapse
Affiliation(s)
| | | | - Yang Xiao
- Discovery Oncology; Genentech; San Francisco, CA
| | - Linda Rangell
- Department of Pathology; Genentech; San Francisco, CA
| | - Sankar Mohan
- Department of Research Diagnostics; Genentech; San Francisco, CA
| | - Ajay Pandita
- Department of Research Diagnostics; Genentech; San Francisco, CA
| | - Jiping Zha
- Department of Pathology; Genentech; San Francisco, CA
| | | | | |
Collapse
|
19
|
Brodbeck J, Chu F, Edick MG, Rangell L, Bheddah S, Cain G. Fluorescence Compared to Brightfield Detection of CD35 in Lymphoid Follicles of the Monkey to Assess Immunomodulatory Treatment Effect. FASEB J 2012. [DOI: 10.1096/fasebj.26.1_supplement.655.10] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
20
|
Tian H, Biehs B, Warming S, Leong KG, Rangell L, Klein OD, de Sauvage FJ. Erratum: A reserve stem cell population in small intestine renders Lgr5-positive cells dispensable. Nature 2012. [DOI: 10.1038/nature10788] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
21
|
Hsu CL, Lin W, Seshasayee D, Chen YH, Ding X, Lin Z, Suto E, Huang Z, Lee WP, Park H, Xu M, Sun M, Rangell L, Lutman JL, Ulufatu S, Stefanich E, Chalouni C, Sagolla M, Diehl L, Fielder P, Dean B, Balazs M, Martin F. Equilibrative nucleoside transporter 3 deficiency perturbs lysosome function and macrophage homeostasis. Science 2011; 335:89-92. [PMID: 22174130 DOI: 10.1126/science.1213682] [Citation(s) in RCA: 87] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
Lysosomal storage diseases (LSDs) are a group of heterogeneous disorders caused by defects in lysosomal enzymes or transporters, resulting in accumulation of undegraded macromolecules or metabolites. Macrophage numbers are expanded in several LSDs, leading to histiocytosis of unknown pathophysiology. Here, we found that mice lacking the equilibrative nucleoside transporter 3 (ENT3) developed a spontaneous and progressive macrophage-dominated histiocytosis. In the absence of ENT3, defective apoptotic cell clearance led to lysosomal nucleoside buildup, elevated intralysosomal pH, and altered macrophage function. The macrophage accumulation was partly due to increased macrophage colony-stimulating factor and receptor expression and signaling secondary to the lysosomal defects. These studies suggest a cellular and molecular basis for the development of histiocytosis in several human syndromes associated with ENT3 mutations and potentially other LSDs.
Collapse
Affiliation(s)
- Chia-Lin Hsu
- Immunology, Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Tian H, Biehs B, Warming S, Leong KG, Rangell L, Klein OD, de Sauvage FJ. A reserve stem cell population in small intestine renders Lgr5-positive cells dispensable. Nature 2011; 478:255-9. [PMID: 21927002 DOI: 10.1038/nature10408] [Citation(s) in RCA: 873] [Impact Index Per Article: 67.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2011] [Accepted: 08/01/2011] [Indexed: 02/08/2023]
Abstract
The small intestine epithelium renews every 2 to 5 days, making it one of the most regenerative mammalian tissues. Genetic inducible fate mapping studies have identified two principal epithelial stem cell pools in this tissue. One pool consists of columnar Lgr5-expressing cells that cycle rapidly and are present predominantly at the crypt base. The other pool consists of Bmi1-expressing cells that largely reside above the crypt base. However, the relative functions of these two pools and their interrelationship are not understood. Here we specifically ablated Lgr5-expressing cells in mice using a human diphtheria toxin receptor (DTR) gene knocked into the Lgr5 locus. We found that complete loss of the Lgr5-expressing cells did not perturb homeostasis of the epithelium, indicating that other cell types can compensate for the elimination of this population. After ablation of Lgr5-expressing cells, progeny production by Bmi1-expressing cells increased, indicating that Bmi1-expressing stem cells compensate for the loss of Lgr5-expressing cells. Indeed, lineage tracing showed that Bmi1-expressing cells gave rise to Lgr5-expressing cells, pointing to a hierarchy of stem cells in the intestinal epithelium. Our results demonstrate that Lgr5-expressing cells are dispensable for normal intestinal homeostasis, and that in the absence of these cells, Bmi1-expressing cells can serve as an alternative stem cell pool. These data provide the first experimental evidence for the interrelationship between these populations. The Bmi1-expressing stem cells may represent both a reserve stem cell pool in case of injury to the small intestine epithelium and a source for replenishment of the Lgr5-expressing cells under non-pathological conditions.
Collapse
Affiliation(s)
- Hua Tian
- Department of Molecular Biology, Genentech Inc., 1 DNA Way, South San Francisco, California 94080, USA
| | | | | | | | | | | | | |
Collapse
|
23
|
Wilson DG, Phamluong K, Li L, Sun M, Cao TC, Liu PS, Modrusan Z, Sandoval WN, Rangell L, Carano RA, Peterson AS, Solloway MJ. Global defects in collagen secretion in a Mia3/TANGO1 knockout mouse. J Cell Biol 2011. [PMCID: PMC3144406 DOI: 10.1083/jcb.2010071621942c] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
24
|
Wilson DG, Phamluong K, Li L, Sun M, Cao TC, Liu PS, Modrusan Z, Sandoval WN, Rangell L, Carano RAD, Peterson AS, Solloway MJ. Global defects in collagen secretion in a Mia3/TANGO1 knockout mouse. ACTA ACUST UNITED AC 2011; 193:935-51. [PMID: 21606205 PMCID: PMC3105544 DOI: 10.1083/jcb.201007162] [Citation(s) in RCA: 134] [Impact Index Per Article: 10.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/04/2022]
Abstract
Mia3’s contribution to protein secretion is broader than previously realized—its absence impairs collagen deposition and normal development of cartilage and bone. Melanoma inhibitory activity member 3 (MIA3/TANGO1) is an evolutionarily conserved endoplasmic reticulum resident transmembrane protein. Recent in vitro studies have shown that it is required for the loading of collagen VII, but not collagen I, into COPII-coated transport vesicles. In this paper, we show that mice lacking Mia3 are defective for the secretion of numerous collagens, including collagens I, II, III, IV, VII, and IX, from chondrocytes, fibroblasts, endothelial cells, and mural cells. Collagen deposition by these cell types is abnormal, and extracellular matrix composition is compromised. These changes are associated with intracellular accumulation of collagen and the induction of a strong unfolded protein response, primarily within the developing skeleton. Chondrocyte maturation and bone mineralization are severely compromised in Mia3-null embryos, leading to dwarfism and neonatal lethality. Thus, Mia3’s role in protein secretion is much broader than previously realized, and it may, in fact, be required for the efficient secretion of all collagen molecules in higher organisms.
Collapse
Affiliation(s)
- Deanna G Wilson
- Department of Molecular Biology, Genentech, South San Francisco, CA 94080, USA
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Lai CK, Gupta N, Wen X, Rangell L, Chih B, Peterson AS, Bazan J, Li L, Scales SJ. Functional characterization of putative cilia genes by high-content analysis. Mol Biol Cell 2011; 22:1104-19. [PMID: 21289087 PMCID: PMC3069013 DOI: 10.1091/mbc.e10-07-0596] [Citation(s) in RCA: 60] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/14/2010] [Revised: 12/15/2011] [Accepted: 01/21/2011] [Indexed: 01/30/2023] Open
Abstract
Cilia are microtubule-based protrusions from the cell surface that are involved in a number of essential signaling pathways, yet little is known about many of the proteins that regulate their structure and function. A number of putative cilia genes have been identified by proteomics and comparative sequence analyses, but functional data are lacking for the vast majority. We therefore monitored the effects in three cell lines of small interfering RNA (siRNA) knockdown of 40 of these genes by high-content analysis. We assayed cilia number, length, and transport of two different cargoes (membranous serotonin receptor 6-green fluorescent protein [HTR6-GFP] and the endogenous Hedgehog [Hh] pathway transcription factor Gli3) by immunofluorescence microscopy; and cilia function using a Gli-luciferase Hh signaling assay. Hh signaling was most sensitive to perturbations, with or without visible structural cilia defects. Validated hits include Ssa2 and mC21orf2 with ciliation defects; Ift46 with short cilia; Ptpdc1 and Iqub with elongated cilia; and Arl3, Nme7, and Ssna1 with distinct ciliary transport but not length defects. Our data confirm various ciliary roles for several ciliome proteins and show it is possible to uncouple ciliary cargo transport from cilia formation in vertebrates.
Collapse
Affiliation(s)
- Cary K. Lai
- Department of Molecular Biology, Genetech, South San Francisco, CA 94080
| | - Nidhi Gupta
- Department of Molecular Biology, Genetech, South San Francisco, CA 94080
| | - Xiaohui Wen
- Department of Molecular Biology, Genetech, South San Francisco, CA 94080
| | | | - Ben Chih
- Department of Molecular Biology, Genetech, South San Francisco, CA 94080
| | - Andrew S. Peterson
- Department of Molecular Biology, Genetech, South San Francisco, CA 94080
| | - J. Fernando Bazan
- Protein Engineering and Structural Biology, Genetech, South San Francisco, CA 94080
| | - Li Li
- Bioinformatics, Genentech, South San Francisco, CA 94080
| | - Suzie J. Scales
- Department of Molecular Biology, Genetech, South San Francisco, CA 94080
| |
Collapse
|
26
|
Abstract
The Esx-1 (type VII) secretion system is critical for virulence of both Mycobacterium tuberculosis and Mycobacterium marinum, and is highly conserved between the two species. Despite its importance, there has been no direct visualization of Esx-1 secretion until now. In M. marinum, we show that secretion of Mh3864, a novel Esx-1 substrate that remains partially cell wall–associated after translocation, occurred in polar regions, indicating that Esx-1 secretion takes place in these regions. Analysis of Esx-1 secretion in infected host cells suggested that Esx-1 activity is similarly localized in vivo. A core component of the Esx-1 apparatus, Mh3870, also localized to bacterial poles, showing a preference for new poles with active cell wall peptidoglycan (PGN) synthesis. This work demonstrates that the Esx-1 secretion machine localizes to, and is active at, the bacterial poles. Thus, virulence-related protein secretion is localized in mycobacteria, suggesting new potential therapeutic targets, which are urgently needed. Mycobacteria represent a major human health problem globally, and there is a pressing need to identify novel processes and mechanisms including therapeutic targets. The Esx-1 secretion system is required for both Mycobacterium tuberculosis and Mycobacterium marinum to cause disease, and is absent from vaccine strains such as Mycobacterium bovis BCG. Esx-1 is functionally conserved between M. tuberculosis and the experimentally amenable M. marinum, which is increasingly used to study this secretory system. Bacterial cells are spatially highly organized; in particular, pathogenic bacteria may localize virulence-related protein secretion to specific regions within the cell envelope, a feature that is generally believed to be important for virulence. However, it has not been known whether Esx-1 is compartmentalized. Our work represents the first visualization of protein secretion in mycobacteria in general. Specifically, we show that the Esx-1 apparatus localizes to, and is active at, the bacterial poles in M. marinum. These findings suggest previously unappreciated mechanisms governing localization of protein secretion in mycobacteria, potentially including new therapeutic targets.
Collapse
Affiliation(s)
- Fredric Carlsson
- Department of Microbial Pathogenesis, Genentech Inc., South San Francisco, California, United States of America
- * E-mail: (FC); (EJB)
| | - Shilpa A. Joshi
- Department of Microbial Pathogenesis, Genentech Inc., South San Francisco, California, United States of America
| | - Linda Rangell
- Department of Pathology, Genentech Inc., South San Francisco, California, United States of America
| | - Eric J. Brown
- Department of Microbial Pathogenesis, Genentech Inc., South San Francisco, California, United States of America
- * E-mail: (FC); (EJB)
| |
Collapse
|
27
|
Van Alstine Bishop CD, Lin Z, Rangell L, Fuh F, Danilenko D, Berry K, Balazs M, Williams M. Characterization of B cell subsets in cynomolgus monkeys. FASEB J 2008. [DOI: 10.1096/fasebj.22.1_supplement.847.19] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
28
|
Katschke KJ, Helmy KY, Steffek M, Xi H, Yin J, Lee WP, Gribling P, Barck KH, Carano RAD, Taylor RE, Rangell L, Diehl L, Hass PE, Wiesmann C, van Lookeren Campagne M. A novel inhibitor of the alternative pathway of complement reverses inflammation and bone destruction in experimental arthritis. ACTA ACUST UNITED AC 2007; 204:1319-25. [PMID: 17548523 PMCID: PMC2118595 DOI: 10.1084/jem.20070432] [Citation(s) in RCA: 74] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
Abstract
Complement is an important component of the innate and adaptive immune response, yet complement split products generated through activation of each of the three complement pathways (classical, alternative, and lectin) can cause inflammation and tissue destruction. Previous studies have shown that complement activation through the alternative, but not classical, pathway is required to initiate antibody-induced arthritis in mice, but it is unclear if the alternative pathway (AP) plays a role in established disease. Previously, we have shown that human complement receptor of the immunoglobulin superfamily (CRIg) is a selective inhibitor of the AP of complement. Here, we present the crystal structure of murine CRIg and, using mutants, provide evidence that the structural requirements for inhibition of the AP are conserved in human and mouse. A soluble form of CRIg reversed inflammation and bone loss in two experimental models of arthritis by inhibiting the AP of complement in the joint. Our data indicate that the AP of complement is not only required for disease induction, but also disease progression. The extracellular domain of CRIg thus provides a novel tool to study the effects of inhibiting the AP of complement in established disease and constitutes a promising therapeutic with selectivity for a single complement pathway.
Collapse
|
29
|
Gerber HP, Wu X, Yu L, Wiesmann C, Liang XH, Lee CV, Fuh G, Olsson C, Damico L, Xie D, Meng YG, Gutierrez J, Corpuz R, Li B, Hall L, Rangell L, Ferrando R, Lowman H, Peale F, Ferrara N. Mice expressing a humanized form of VEGF-A may provide insights into the safety and efficacy of anti-VEGF antibodies. Proc Natl Acad Sci U S A 2007; 104:3478-83. [PMID: 17360669 PMCID: PMC1805509 DOI: 10.1073/pnas.0611492104] [Citation(s) in RCA: 91] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
VEGF-A is important in tumor angiogenesis, and a humanized anti-VEGF-A monoclonal antibody (bevacizumab) has been approved by the FDA as a treatment for metastatic colorectal and nonsquamous, non-small-cell lung cancer in combination with chemotherapy. However, contributions of both tumor- and stromal-cell derived VEGF-A to vascularization of human tumors grown in immunodeficient mice hindered direct comparison between the pharmacological effects of anti-VEGF antibodies with different abilities to block host VEGF. Therefore, by gene replacement technology, we engineered mice to express a humanized form of VEGF-A (hum-X VEGF) that is recognized by many anti-VEGF antibodies and has biochemical and biological properties comparable with WT mouse and human VEGF-A. The hum-X VEGF mouse model was then used to compare the activity and safety of a panel of VEGF Mabs with different affinities for VEGF-A. Although in vitro studies clearly showed a correlation between binding affinity and potency at blocking endothelial cell proliferation stimulated by VEGF, in vivo experiments failed to document any consistent correlation between antibody affinity and the ability to inhibit tumor growth and angiogenesis in most animal models. However, higher-affinity antibodies were more likely to result in glomerulosclerosis during long-term treatment.
Collapse
Affiliation(s)
| | - Xiumin Wu
- Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080
| | - Lanlan Yu
- Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080
| | | | | | | | - Germaine Fuh
- Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080
| | | | - Lisa Damico
- Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080
| | - David Xie
- Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080
| | - Y. Gloria Meng
- Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080
| | | | - Racquel Corpuz
- Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080
| | - Bing Li
- Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080
| | - Linda Hall
- Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080
| | - Linda Rangell
- Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080
| | - Ron Ferrando
- Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080
| | - Henry Lowman
- Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080
| | - Franklin Peale
- Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080
| | - Napoleone Ferrara
- Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080
- To whom correspondence should be addressed. E-mail:
| |
Collapse
|
30
|
Fan B, Brennan J, Grant D, Peale F, Rangell L, Kirchhofer D. Hepatocyte growth factor activator inhibitor-1 (HAI-1) is essential for the integrity of basement membranes in the developing placental labyrinth. Dev Biol 2006; 303:222-30. [PMID: 17174946 DOI: 10.1016/j.ydbio.2006.11.005] [Citation(s) in RCA: 51] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2006] [Revised: 10/15/2006] [Accepted: 11/06/2006] [Indexed: 11/27/2022]
Abstract
Hepatocyte growth factor activator inhibitor-1 (HAI-1) is a membrane-associated Kunitz-type serine protease inhibitor that regulates cell surface and extracellular serine proteases involved in tissue remodeling and tumorigenesis, such as HGFA, matriptase, prostasin and hepsin. We generated HAI-1 deficient mice, which died in utero due to placental defects. The HAI-1(-/-) placental labyrinth exhibited a complete failure of vascularization and a compact morphology of the trophoblast layer. Immunofluorescent staining of collagen IV and laminin and electron microscopy analysis revealed that this aberrant labyrinth architecture was associated with disrupted basement membranes located at the interface of chorionic trophoblasts and allantoic mesoderm. Unlike the placental labyrinth, basement membranes and vasculogenesis were normal in embryo and yolk sac. Therefore, basement membrane defects appear to be the underlying cause for the greatly impaired vascularization and trophoblast branching in HAI-1(-/-) placentas. In wild-type placentas, the expression of matriptase and prostasin co-localized with their physiological inhibitor HAI-1 to the labyrinthine trophoblast cells in proximity to basement membranes. In HAI-1(-/-) placentas, both the localization and expression of the two proteases remained unchanged, implying uncontrolled proteolytic activities of the two enzymes. Our study demonstrates the important role of HAI-1 in maintaining the integrity of basement membrane most likely by regulating extracellular proteolytic activities during placental development.
Collapse
Affiliation(s)
- Bin Fan
- Department of Protein Engineering, Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA
| | | | | | | | | | | |
Collapse
|
31
|
Abstract
The evolutionarily conserved actin-related protein (Arp2/3) complex is a key component of actin filament networks that is dynamically regulated by nucleation-promoting and inhibitory factors. Although much is known about actin assembly, the physiologic functions of inhibitory proteins are unclear. We generated coronin 1-/- mice and found that coronin 1 exerted an inhibitory effect on cellular steady-state F-actin formation via an Arp2/3-dependent mechanism. Whereas coronin 1 was required for chemokine-mediated migration, it was dispensable for T cell antigen receptor functions in T cells. Moreover, actin dynamics, through a mitochondrial pathway, was linked to lymphocyte homeostasis.
Collapse
Affiliation(s)
- Niko Föger
- Department of Immunology, Genentech, Incorporated, 1 DNA Way, South San Francisco, CA 94080, USA
| | | | | | | |
Collapse
|
32
|
van Lookeren Campagne M, Helmy K, Katschke K, Lee W, Zhang Y, Rangell L, Taylor R, Diehl L, Steffek M, Hass P. F.45. CRIg Inhibits the Alternative Pathway of Complement in Mouse Models of Arthritis. Clin Immunol 2006. [DOI: 10.1016/j.clim.2006.04.085] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
33
|
Kong-Beltran M, Seshagiri S, Zha J, Zhu W, Bhawe K, Mendoza N, Holcomb T, Pujara K, Stinson J, Fu L, Severin C, Rangell L, Schwall R, Amler L, Wickramasinghe D, Yauch R. Somatic mutations lead to an oncogenic deletion of met in lung cancer. Cancer Res 2006; 66:283-9. [PMID: 16397241 DOI: 10.1158/0008-5472.can-05-2749] [Citation(s) in RCA: 359] [Impact Index Per Article: 19.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Activating mutations in receptor tyrosine kinases play a critical role in oncogenesis. Despite evidence that Met kinase is deregulated in human cancer, the role of activating mutations in cancers other than renal papillary carcinoma has not been well defined. Here we report the identification of somatic intronic mutations of Met kinase that lead to an alternatively spliced transcript in lung cancer, which encodes a deletion of the juxtamembrane domain resulting in the loss of Cbl E3-ligase binding. The mutant receptor exhibits decreased ubiquitination and delayed down-regulation correlating with elevated, distinct Met expression in primary tumors harboring the deleted receptor. As a consequence, phospho-Met and downstream mitogen-activated protein kinase activation is sustained on ligand stimulation. Cells expressing the Met deletion reveal enhanced ligand-mediated proliferation and significant in vivo tumor growth. A hepatocyte growth factor competitive Met antagonist inhibits receptor activation and proliferation in tumor cells harboring the Met deletion, suggesting the important role played by ligand-dependent Met activation and the potential for anticancer therapy. These results support a critical role for Met in lung cancer and somatic mutation-driven splicing of an oncogene that leads to a different mechanism for tyrosine kinase activation through altered receptor down-regulation in human cancer.
Collapse
Affiliation(s)
- Monica Kong-Beltran
- Department of Molecular Oncology, Genentech, Inc., South San Francisco, California 94114, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
34
|
John GB, Shang Y, Li L, Renken C, Mannella CA, Selker JML, Rangell L, Bennett MJ, Zha J. The mitochondrial inner membrane protein mitofilin controls cristae morphology. Mol Biol Cell 2005; 16:1543-54. [PMID: 15647377 PMCID: PMC551514 DOI: 10.1091/mbc.e04-08-0697] [Citation(s) in RCA: 359] [Impact Index Per Article: 18.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023] Open
Abstract
Mitochondria are complex organelles with a highly dynamic distribution and internal organization. Here, we demonstrate that mitofilin, a previously identified mitochondrial protein of unknown function, controls mitochondrial cristae morphology. Mitofilin is enriched in the narrow space between the inner boundary and the outer membranes, where it forms a homotypic interaction and assembles into a large multimeric protein complex. Down-regulation of mitofilin in HeLa cells by using specific small interfering RNA lead to decreased cellular proliferation and increased apoptosis, suggesting abnormal mitochondrial function. Although gross mitochondrial fission and fusion seemed normal, ultrastructural studies revealed disorganized mitochondrial inner membrane. Inner membranes failed to form tubular or vesicular cristae and showed as closely packed stacks of membrane sheets that fused intermittently, resulting in a complex maze of membranous network. Electron microscopic tomography estimated a substantial increase in inner:outer membrane ratio, whereas no cristae junctions were detected. In addition, mitochondria subsequently exhibited increased reactive oxygen species production and membrane potential. Although metabolic flux increased due to mitofilin deficiency, mitochondrial oxidative phosphorylation was not increased accordingly. We propose that mitofilin is a critical organizer of the mitochondrial cristae morphology and thus indispensable for normal mitochondrial function.
Collapse
Affiliation(s)
- George B John
- Department of Pathology, University of Texas Southwestern Medical Center at Dallas, Dallas, TX 75390, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Ross S, Spencer SD, Holcomb I, Tan C, Hongo J, Devaux B, Rangell L, Keller GA, Schow P, Steeves RM, Lutz RJ, Frantz G, Hillan K, Peale F, Tobin P, Eberhard D, Rubin MA, Lasky LA, Koeppen H. Prostate stem cell antigen as therapy target: tissue expression and in vivo efficacy of an immunoconjugate. Cancer Res 2002; 62:2546-53. [PMID: 11980648] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/24/2023]
Abstract
We conducted an expression analysis of prostate stem cell antigen (PSCA)in normal urogenital tissues, benign prostatic hyperplasia (n = 21), prostatic intraepithelial neoplasia (n = 33), and primary (n = 137) and metastatic (n = 42) prostate adenocarcinoma, using isotopic in situ hybridization on tissue microarrays. In normal prostate, we observe PSCA expression in the terminally differentiated, secretory epithelium; strong expression was also seen in normal urothelium. Forty-eight percent of primary and 64% of metastatic prostatic adenocarcinomas expressed PSCA RNA. Our studies did not confirm a positive correlation between level of PSCA RNA expression and high Gleason grade. We characterized monoclonal anti-PSCA antibodies that recognize PSCA expressed on the surface of live cells, are efficiently internalized after antigen recognition, and kill tumor cells in vitro in an antigen-specific fashion upon conjugation with maytansinoid. Unconjugated anti-PSCA antibodies demonstrated efficacy against PSCA-positive tumors by delaying progressive tumor growth in vivo. Maytansinoid-conjugated antibodies caused complete regression of established tumors in a large proportion of animals. Our results strongly suggest that maytansinoid-conjugated anti-PSCA monoclonal antibodies should be evaluated as a therapeutic modality for patients with advanced prostate cancer.
Collapse
Affiliation(s)
- Sarajane Ross
- Department of Pathology, Genentech, Inc., South San Francisco, California 94080, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
36
|
LeCouter J, Kowalski J, Foster J, Hass P, Zhang Z, Dillard-Telm L, Frantz G, Rangell L, DeGuzman L, Keller GA, Peale F, Gurney A, Hillan KJ, Ferrara N. Identification of an angiogenic mitogen selective for endocrine gland endothelium. Nature 2001; 412:877-84. [PMID: 11528470 DOI: 10.1038/35091000] [Citation(s) in RCA: 396] [Impact Index Per Article: 17.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Abstract
The known endothelial mitogens stimulate growth of vascular endothelial cells without regard to their tissue of origin. Here we report a growth factor that is expressed largely in one type of tissue and acts selectively on one type of endothelium. This molecule, called endocrine-gland-derived vascular endothelial growth factor (EG-VEGF), induced proliferation, migration and fenestration (the formation of membrane discontinuities) in capillary endothelial cells derived from endocrine glands. However, EG-VEGF had little or no effect on a variety of other endothelial and non-endothelial cell types tested. Similar to VEGF, EG-VEGF possesses a HIF-1 binding site, and its expression is induced by hypoxia. Both EG-VEGF and VEGF resulted in extensive angiogenesis and cyst formation when delivered in the ovary. However, unlike VEGF, EG-VEGF failed to promote angiogenesis in the cornea or skeletal muscle. Expression of human EG-VEGF messenger RNA is restricted to the steroidogenic glands, ovary, testis, adrenal and placenta and is often complementary to the expression of VEGF, suggesting that these molecules function in a coordinated manner. EG-VEGF is an example of a class of highly specific mitogens that act to regulate proliferation and differentiation of the vascular endothelium in a tissue-specific manner.
Collapse
Affiliation(s)
- J LeCouter
- Department of Molecular Oncology, Genentech Inc., South San Francisco, CA 94080, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Xin X, Yang S, Ingle G, Zlot C, Rangell L, Kowalski J, Schwall R, Ferrara N, Gerritsen ME. Hepatocyte growth factor enhances vascular endothelial growth factor-induced angiogenesis in vitro and in vivo. Am J Pathol 2001; 158:1111-20. [PMID: 11238059 PMCID: PMC1850376 DOI: 10.1016/s0002-9440(10)64058-8] [Citation(s) in RCA: 280] [Impact Index Per Article: 12.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
Vascular endothelial growth factor (VEGF) is an important mediator of angiogenesis in both physiological and pathological processes. Hepatocyte growth factor (HGF) is a mesenchyme-derived mitogen that also stimulates cell migration, and branching and/or tubular morphogenesis of epithelial and endothelial cells. In the present study, we tested the hypothesis that simultaneous administration of HGF and VEGF would synergistically promote new blood vessel formation. HGF acted in concert with VEGF to promote human endothelial cell survival and tubulogenesis in 3-D type I collagen gels, a response that did not occur with either growth factor alone. The synergistic effects of VEGF and HGF on endothelial survival correlated with greatly augmented mRNA levels for the anti-apoptotic genes Bcl-2 and A1. Co-culture experiments with human neonatal dermal fibroblasts and human umbilical vein endothelial cells demonstrated that neonatal dermal fibroblasts, in combination with VEGF, stimulated human umbilical vein endothelial cells tubulogenesis through the paracrine secretion of HGF. Finally, in vivo experiments demonstrated that the combination of HGF and VEGF increased neovascularization in the rat corneal assay greater than either growth factor alone. We suggest that combination therapy using HGF and VEGF co-administration may provide a more effective strategy to achieve therapeutic angiogenesis.
Collapse
Affiliation(s)
- X Xin
- Department of Cardiovascular Research, Genentech Inc., South San Francisco, CA 94080, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
38
|
|
39
|
Snyder WB, Koller A, Choy AJ, Johnson MA, Cregg JM, Rangell L, Keller GA, Subramani S. Pex17p is required for import of both peroxisome membrane and lumenal proteins and interacts with Pex19p and the peroxisome targeting signal-receptor docking complex in Pichia pastoris. Mol Biol Cell 1999; 10:4005-19. [PMID: 10588639 PMCID: PMC25739 DOI: 10.1091/mbc.10.12.4005] [Citation(s) in RCA: 52] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022] Open
Abstract
Pichia pastoris PEX17 was cloned by complementation of a peroxisome-deficient strain obtained from a novel screen for mutants disrupted in the localization of a peroxisomal membrane protein (PMP) reporter. PEX17 encodes a 267-amino-acid protein with low identity (18%) to the previously characterized Saccharomyces cerevisiae Pex17p. Like ScPex17p, PpPex17p contains a putative transmembrane domain near the amino terminus and two carboxyl-terminal coiled-coil regions. PpPex17p behaves as an integral PMP with a cytosolic carboxyl-terminal domain. pex17Delta mutants accumulate peroxisomal matrix proteins and certain integral PMPs in the cytosol, suggesting a critical role for Pex17p in their localization. Peroxisome remnants were observed in the pex17Delta mutant by morphological and biochemical means, suggesting that Pex17p is not absolutely required for remnant formation. Yeast two-hybrid analysis demonstrated that the carboxyl terminus of Pex19p was required for interaction with Pex17p lacking the carboxyl-terminal coiled-coil domains. Biochemical evidence confirmed the interaction between Pex19p and Pex17p. Additionally, Pex17p cross-linked to components of the peroxisome targeting signal-receptor docking complex, which unexpectedly contained Pex3p. Our evidence suggests the existence of distinct subcomplexes that contain separable pools of Pex3p, Pex19p, Pex17p, Pex14p, and the peroxisome targeting signal receptors. These distinct pools may serve different purposes for the import of matrix proteins or PMPs.
Collapse
Affiliation(s)
- W B Snyder
- Department of Biology, University of California, San Diego, La Jolla, California 92093-0322, USA
| | | | | | | | | | | | | | | |
Collapse
|
40
|
Koller A, Snyder WB, Faber KN, Wenzel TJ, Rangell L, Keller GA, Subramani S. Pex22p of Pichia pastoris, essential for peroxisomal matrix protein import, anchors the ubiquitin-conjugating enzyme, Pex4p, on the peroxisomal membrane. J Cell Biol 1999; 146:99-112. [PMID: 10402463 PMCID: PMC2199742 DOI: 10.1083/jcb.146.1.99] [Citation(s) in RCA: 75] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
We isolated a Pichia pastoris mutant that was unable to grow on the peroxisome-requiring media, methanol and oleate. Cloning the gene by complementation revealed that the encoded protein, Pex22p, is a new peroxin. A Deltapex22 strain does not grow on methanol or oleate and is unable to import peroxisomal matrix proteins. However, this strain targets peroxisomal membrane proteins to membranes, most likely peroxisomal remnants, detectable by fluorescence and electron microscopy. Pex22p, composed of 187 amino acids, is an integral peroxisomal membrane protein with its NH2 terminus in the matrix and its COOH terminus in the cytosol. It contains a 25-amino acid peroxisome membrane-targeting signal at its NH2 terminus. Pex22p interacts with the ubiquitin-conjugating enzyme Pex4p, a peripheral peroxisomal membrane protein, in vivo, and in a yeast two-hybrid experiment. Pex22p is required for the peroxisomal localization of Pex4p and in strains lacking Pex22p, the Pex4p is cytosolic and unstable. Therefore, Pex22p anchors Pex4p at the peroxisomal membrane. Strains that do not express Pex4p or Pex22p have similar phenotypes and lack Pex5p, suggesting that Pex4p and Pex22p act at the same step in peroxisome biogenesis. The Saccharomyces cerevisiae hypothetical protein, Yaf5p, is the functional homologue of P. pastoris Pex22p.
Collapse
Affiliation(s)
- Antonius Koller
- Department of Biology, University of California San Diego, La Jolla, California 92093-0322
| | - William B. Snyder
- Department of Biology, University of California San Diego, La Jolla, California 92093-0322
| | - Klaas Nico Faber
- Department of Biology, University of California San Diego, La Jolla, California 92093-0322
| | - Thibaut J. Wenzel
- Department of Biology, University of California San Diego, La Jolla, California 92093-0322
| | - Linda Rangell
- Pharmacological Science, Genentech, South San Francisco, California 94080
| | - Gilbert A. Keller
- Pharmacological Science, Genentech, South San Francisco, California 94080
| | - Suresh Subramani
- Department of Biology, University of California San Diego, La Jolla, California 92093-0322
| |
Collapse
|
41
|
Snyder WB, Faber KN, Wenzel TJ, Koller A, Lüers GH, Rangell L, Keller GA, Subramani S. Pex19p interacts with Pex3p and Pex10p and is essential for peroxisome biogenesis in Pichia pastoris. Mol Biol Cell 1999; 10:1745-61. [PMID: 10359594 PMCID: PMC25367 DOI: 10.1091/mbc.10.6.1745] [Citation(s) in RCA: 97] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022] Open
Abstract
We report the cloning and characterization of Pichia pastoris PEX19 by complementation of a peroxisome-deficient mutant strain. Import of peroxisomal targeting signal 1- and 2-containing peroxisomal matrix proteins is defective in pex19 mutants. PEX19 encodes a hydrophilic 299-amino acid protein with sequence similarity to Saccharomyces cerevisiae Pex19p and human and Chinese hamster PxF, all farnesylated proteins, as well as hypothetical proteins from Caenorhabditis elegans and Schizosaccharomyces pombe. The farnesylation consensus is conserved in PpPex19p but dispensable for function and appears unmodified under the conditions tested. Pex19p localizes predominantly to the cytosolic fraction. Biochemical and two-hybrid analyses confirmed that Pex19p interacts with Pex3p, as seen in S. cerevisiae, but unexpectedly also with Pex10p. Two-hybrid analysis demonstrated that the amino-terminal 42 amino acids of Pex19p interact with the carboxyl-terminal 335 amino acids of Pex3p. In addition, the extreme carboxyl terminus of Pex19p (67 amino acids) is required for interaction with the amino-terminal 380 amino acids of Pex10p. Biochemical and immunofluorescence microscopy analyses of pex19Delta cells identified the membrane protein Pex3p in peroxisome remnants that were not previously observed in S. cerevisiae. These small vesicular and tubular (early) remnants are morphologically distinct from other Pppex mutant (late) remnants, suggesting that Pex19p functions at an early stage of peroxisome biogenesis.
Collapse
Affiliation(s)
- W B Snyder
- Department of Biology, University of California, San Diego, La Jolla, California 92093-0322, USA
| | | | | | | | | | | | | | | |
Collapse
|
42
|
Gerber HP, Hillan KJ, Ryan AM, Kowalski J, Keller GA, Rangell L, Wright BD, Radtke F, Aguet M, Ferrara N. VEGF is required for growth and survival in neonatal mice. Development 1999; 126:1149-59. [PMID: 10021335 DOI: 10.1242/dev.126.6.1149] [Citation(s) in RCA: 609] [Impact Index Per Article: 24.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
We employed two independent approaches to inactivate the angiogenic protein VEGF in newborn mice: inducible, Cre-loxP- mediated gene targeting, or administration of mFlt(1–3)-IgG, a soluble VEGF receptor chimeric protein. Partial inhibition of VEGF achieved by inducible gene targeting resulted in increased mortality, stunted body growth and impaired organ development, most notably of the liver. Administration of mFlt(1–3)-IgG, which achieves a higher degree of VEGF inhibition, resulted in nearly complete growth arrest and lethality. Ultrastructural analysis documented alterations in endothelial and other cell types. Histological and biochemical changes consistent with liver and renal failure were observed. Endothelial cells isolated from the liver of mFlt(1–3)-IgG-treated neonates demonstrated an increased apoptotic index, indicating that VEGF is required not only for proliferation but also for survival of endothelial cells. However, such treatment resulted in less significant alterations as the animal matured, and the dependence on VEGF was eventually lost some time after the fourth postnatal week. Administration of mFlt(1–3)-IgG to juvenile mice failed to induce apoptosis in liver endothelial cells. Thus, VEGF is essential for growth and survival in early postnatal life. However, in the fully developed animal, VEGF is likely to be involved primarily in active angiogenesis processes such as corpus luteum development.
Collapse
Affiliation(s)
- H P Gerber
- Departments of Cardiovascular Research and Pathology, Genentech, Inc., South San Francisco, CA 94080, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Bunting S, Widmer R, Lipari T, Rangell L, Steinmetz H, Carver-Moore K, Moore MW, Keller GA, de Sauvage FJ. Normal platelets and megakaryocytes are produced in vivo in the absence of thrombopoietin. Blood 1997; 90:3423-9. [PMID: 9345025] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
Abstract
Thrombopoietin (TPO) has been established as the major regulator of megakaryocyte and platelet production. In vitro and in vivo studies have demonstrated that TPO affects both megakaryocyte proliferation and maturation. In vitro, TPO has been reported to be essential for full development of megakaryocytes and platelets. These studies are in contrast to results observed in vivo in mice deficient in the TPO or c-mpl gene (TPO-/- and c-mpl-/-). Both TPO-/- and c-mpl-/- mice exhibit a 90% reduction in megakaryocyte and platelet levels. But even with this small number of circulating platelets, these mice do not have any excessive bleeding. Ultrastructural analysis indicates that platelets and megakaryocytes present in the knockout mice are morphologically normal. Characterization of platelet function shows that platelets from knockout mice are functionally identical to the wild-type platelets as measured by upregulation of 125I-fibrinogen binding to platelets in response to adenosine diphosphate (ADP) stimulation and by platelet attachment to the immobilized extracellular matrix proteins, collagen and von Willebrand factor (vWF). These results demonstrate that in vivo, TPO is required for the control of megakaryocyte and platelet number but not for their maturation. Other factors with megakaryocytopoietic activity may be able to compensate for the maturational role of TPO and lead to the formation of normal megakaryocytes and platelets in TPO-/- and c-mpl-/- mice.
Collapse
Affiliation(s)
- S Bunting
- Department of Molecular Oncology, Genentech Inc, South San Francisco, CA 94080, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
44
|
Rangell L. Psychoanalytic realities and the analytic goal. Int J Psychoanal 1995; 76 ( Pt 1):15-8. [PMID: 7775028] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
|
45
|
Abstract
Castration is not a metaphor within the array of psychoanalytic theories, but a pathological belief operative in the unconscious, which originated during the period of childhood sexuality. Of the two major anxieties, separation and castration, castration anxiety is the most overlooked in clinical discourse and theoretical awareness. Castration conflicts have a developmental history and are composed of phases as much as separation-individuation is. These extend from the preoedipal to the oedipal years and beyond and, as separation conflicts, persist throughout life. Clinical material is demonstrated from across the diagnostic spectrum and all developmental levels. Phylogenetic studies are corroborative. As loss of love is a wider derivative of separation anxiety, castration anxiety radiates out to wider fears of invasion and injury to the body. The transference neurosis is more attuned to encompass separation than castration conflicts. This stratum of psychopathology makes reconstruction and the recovery of historical data indispensable.
Collapse
|
46
|
Abstract
The historical development of preoedipality in evolving psychoanalytic theory is traced. Particular reference is paid to the elaboration by Mahler of the separation-individuation phase and the specific rapprochement conflict and crisis within it. In addition to the valuable contributions these discoveries have brought about, the tendency is noted for every new locus of interest to be obscured by excessive claims, and distorted by overuse and reductionism to explain complex and multidetermined behavior. This leads to the question of the specific and nonspecific in analytic reconstruction. Psychoanalysis invites a search for the specific superimposed upon the general. What I believe is nonspecific is the experience of the traumatic state, variable in degree, and the anxiety always adherent to it. The cognitive and historical data which initiated and maintain these affective states need to be arrived at with clinical accuracy and sustaining data, transference and historical. With discipline and restraint, and effective clinical bridges for interpretation, reapprochement and other distant preoedipal determinants can be pointed to in analytic reconstruction with confidence and profit to the analysis. Clinical examples are cited of valid and therapeutically effective reconstruction of early infantile traumas, including reapprochement, as well as instances in which significant etiologic determinants from contiguous phases are fused and continuous. Reapprochement plays an important role, but the temptation to isolate it is to be tempered with an openness to all levels and an awareness of the continuing developmental line. Such a wide etiologic spectrum is in keeping with the total range of observations and formulations made by Mahler, from the psychological birth of the infant, through separation-individuation, to phenomena and stages long after the attainment of object constancy.
Collapse
|
47
|
Rangell L. The future of psychoanalysis: the scientific crossroads. Psychoanal Q 1988; 57:313-40. [PMID: 3420210] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
|
48
|
|
49
|
Rangell L. A core process in psychoanalytic treatment. Psychoanal Q 1987; 56:222-49. [PMID: 3562701] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
A core mechanism of the psychoanalytic process is described. This involves the effects of treatment on an ongoing "unconscious intrapsychic process," which has specific points of vulnerability to pathology. The concept of an intrapsychic process described by the author in previous publications is an expanded formulation of the idea of thought as trial action and of the signal theory of anxiety. The psychoanalytic method alters the functioning of the ego astride this unconscious process, strengthening its control over anxiety, defense, trauma, and symptom formation. This is mutative in the psychoanalytic method.
Collapse
|
50
|
|